Northwire Canada EditionMonday, October 19, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4169.90 −0.3% SILVER 57.40 +0.2% COPPER 6.53 −0.6% OIL 97.56 −1.5% PALLADIUM 1124.25 +0.5% SAGE 0.110 +0.0% REC 0.050 +0.0% NICN 0.125 +8.7% TRX 1.48 −2.0% VLC 0.215 +2.4% TIGR 0.640 +3.2% TUO 1.42 −0.7% SVG 0.125 +0.0% VCU 1.02 +0.0% MACK 3.17 +2.3% COSA 0.380 −3.8% WGLD 0.130 +0.0% OSM 0.025 +0.0% TOM 0.145 +3.6% ALS 56.00 −1.0% FMAN 0.300 −1.6% GOLD 4169.90 −0.3% SILVER 57.40 +0.2% COPPER 6.53 −0.6% OIL 97.56 −1.5% PALLADIUM 1124.25 +0.5% SAGE 0.110 +0.0% REC 0.050 +0.0% NICN 0.125 +8.7% TRX 1.48 −2.0% VLC 0.215 +2.4% TIGR 0.640 +3.2% TUO 1.42 −0.7% SVG 0.125 +0.0% VCU 1.02 +0.0% MACK 3.17 +2.3% COSA 0.380 −3.8% WGLD 0.130 +0.0% OSM 0.025 +0.0% TOM 0.145 +3.6% ALS 56.00 −1.0% FMAN 0.300 −1.6%
Production / Operations

PanGenomic Health Expands NaraCare.AI Platform with Launch of DNA Testing Program

By The Northwire Desk — AI Analysis Oct 20, 2025 · 20:00 NARA · 1.58 PanGenomic Health Inc.
NARA · Price

Executive Summary

  • PanGenomic Health announced the launch of its Agenta DNA testing program, integrated with the Nara.Care AI platform for personalized wellness.
  • The DNA test kits will be sold to Canadian consumers this quarter via the Agenta Health e‑commerce site, with a planned U.S. rollout in early 2026.
  • The initiative aims to enrich the AI platform with genetic data to deliver actionable insights on diet, fitness, metabolism, brain function and overall health.

Key Details

  • Program Launch: Introduction of Agenta branded DNA testing kits as part of the Nara.Care AI platform.
  • Market Roll‑out: Initial sales in Canada this quarter; expansion into the United States targeted for early 2026.
  • Distribution Channel: Kits available for purchase on the Agenta Health e‑commerce site (www.agentahealth.store).
  • Strategic Partner: Collaboration with a leading developer of DNA testing technologies (partner not named).
  • Platform Integration: Genetic data from Agenta tests will feed into Nara.Care AI to generate personalized wellness recommendations covering diet, fitness, metabolism, brain function and overall health.
  • Data Privacy: Company commits to implementing safeguards to protect the privacy of genomic and health data.
  • Leadership Quote: “We believe consumers are looking for better information about their unique health situation…the foundation of our NaraCare.AI platform is personalization…” – Maryam Marissen, President & CEO.

Notable Quotes

“The foundation of our NaraCare.AI platform is personalization, and there is no better baseline for that foundation than incorporating the unique genetic makeup of each individual.” – Maryam Marissen, President & CEO

All boilerplate, forward‑looking disclaimer, and contact information have been omitted per instructions.

Read the original news release →

More from PanGenomic Health Inc.

May 01, 2026 · 00:10

PanGenomic Health Faces Dilution as Ayla BioScience Deal Reshapes Ownership Structure

Earnings Apr 14, 2026 · 09:45

Tagline: PanGenomic Shareholders Face 85% Dilution in Ayla BioScience Takeover Bid

Financings Dec 29, 2025 · 18:56

Pangenomic arranges $2-million private placement

Financings Dec 29, 2025 · 18:50

PanGenomic Health Announces Non-Brokered Private Placement of up to $2,000,000

Financings Nov 05, 2025 · 03:52

Pangenomic enters LOI for distribution deal with Ayla

M&A / Property Nov 04, 2025 · 20:00

PanGenomic Health Signs Letter of Intent with Ayla BioScience

M&A / Property